- Home
- CGO vs CRDL Comparison
CGO vs CRDL Comparison
Compare CGO & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- CRDL
- Stock Information
- Founded
- CGO 2004
- CRDL 2017
- Country
- CGO United States
- CRDL Canada
- Employees
- CGO N/A
- CRDL N/A
- Industry
- CGO Investment Managers
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGO Finance
- CRDL Health Care
- Exchange
- CGO Nasdaq
- CRDL Nasdaq
- Market Cap
- CGO 111.7M
- CRDL 102.0M
- IPO Year
- CGO N/A
- CRDL N/A
- Fundamental
- Price
- CGO $11.52
- CRDL $1.20
- Analyst Decision
- CGO
- CRDL Strong Buy
- Analyst Count
- CGO 0
- CRDL 3
- Target Price
- CGO N/A
- CRDL $9.00
- AVG Volume (30 Days)
- CGO 34.7K
- CRDL 274.8K
- Earning Date
- CGO 01-01-0001
- CRDL 03-31-2025
- Dividend Yield
- CGO 9.25%
- CRDL N/A
- EPS Growth
- CGO N/A
- CRDL N/A
- EPS
- CGO N/A
- CRDL N/A
- Revenue
- CGO N/A
- CRDL N/A
- Revenue This Year
- CGO N/A
- CRDL N/A
- Revenue Next Year
- CGO N/A
- CRDL N/A
- P/E Ratio
- CGO N/A
- CRDL N/A
- Revenue Growth
- CGO N/A
- CRDL N/A
- 52 Week Low
- CGO $7.90
- CRDL $1.15
- 52 Week High
- CGO $10.93
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- CGO 50.62
- CRDL 41.60
- Support Level
- CGO $11.41
- CRDL $1.15
- Resistance Level
- CGO $11.71
- CRDL $1.51
- Average True Range (ATR)
- CGO 0.18
- CRDL 0.10
- MACD
- CGO 0.01
- CRDL -0.01
- Stochastic Oscillator
- CGO 60.00
- CRDL 13.65
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in global equities, convertible securities, and high-yield corporate bonds.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.